These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24590542)

  • 1. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014).
    Parrott AC
    Hum Psychopharmacol; 2014 Mar; 29(2):109-19. PubMed ID: 24590542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.
    Parrott AC
    Hum Psychopharmacol; 2013 Jul; 28(4):289-307. PubMed ID: 23881877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".
    Doblin R; Greer G; Holland J; Jerome L; Mithoefer MC; Sessa B
    Hum Psychopharmacol; 2014 Mar; 29(2):105-8. PubMed ID: 24590541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users.
    Parrott AC
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1466-84. PubMed ID: 23660456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory deficits associated with recreational use of "ecstasy" (MDMA).
    Morgan MJ
    Psychopharmacology (Berl); 1999 Jan; 141(1):30-6. PubMed ID: 9952062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and promise for the MDMA drug development program.
    Feduccia AA; Holland J; Mithoefer MC
    Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation.
    Parrott AC
    Br J Pharmacol; 2012 Jul; 166(5):1518-20; discussion 1521-2. PubMed ID: 22404300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a case for MDMA-assisted psychotherapy in the UK?
    Sessa B
    J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can MDMA play a role in the treatment of substance abuse?
    Jerome L; Schuster S; Yazar-Klosinski BB
    Curr Drug Abuse Rev; 2013 Mar; 6(1):54-62. PubMed ID: 23627786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential dangers of using MDMA for psychotherapy.
    Parrott AC
    J Psychoactive Drugs; 2014; 46(1):37-43. PubMed ID: 24830184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced memory skills and increased hair cortisol levels in recent Ecstasy/MDMA users: significant but independent neurocognitive and neurohormonal deficits.
    Downey LA; Sands H; Jones L; Clow A; Evans P; Stalder T; Parrott AC
    Hum Psychopharmacol; 2015 May; 30(3):199-207. PubMed ID: 25900184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MDMA or ecstasy: pharmacologic, toxicologic and clinical aspects].
    Prada C; Alvarez FJ
    Med Clin (Barc); 1996 Oct; 107(14):549-55. PubMed ID: 8999216
    [No Abstract]   [Full Text] [Related]  

  • 14. Altered states: the clinical effects of Ecstasy.
    Cole JC; Sumnall HR
    Pharmacol Ther; 2003 Apr; 98(1):35-58. PubMed ID: 12667887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.
    Parrott AC; Milani RM; Gouzoulis-Mayfrank E; Daumann J
    J Neural Transm (Vienna); 2007; 114(8):959-68. PubMed ID: 17520319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.
    Parrott AC
    Psychopharmacology (Berl); 2007 Apr; 191(2):181-93. PubMed ID: 17297639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
    Hanson KL; Luciana M
    J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence.
    Dafters RI; Duffy F; O'Donnell PJ; Bouquet C
    Psychopharmacology (Berl); 1999 Jul; 145(1):82-90. PubMed ID: 10445376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.